Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Use of aspirin in reduction of mortality of COVID-19 patients: A meta-analysis.

Tytuł :
Use of aspirin in reduction of mortality of COVID-19 patients: A meta-analysis.
Autorzy :
Srivastava R; Department of Pharmacology and Clinical Research, Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi, India.
Kumar A; Department of Pharmacology and Clinical Research, Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi, India.; Department of Pharmacology, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences & Research University (DPSRU), New Delhi, India.
Pokaż więcej
Źródło :
International journal of clinical practice [Int J Clin Pract] 2021 Jun 12, pp. e14515. Date of Electronic Publication: 2021 Jun 12.
Publication Model :
Ahead of Print
Typ publikacji :
Meta-Analysis
Język :
English
Imprint Name(s) :
Publication: 2003- : Oxford, U.K. : Wiley
Original Publication: Esher [England] ; Bronxville, N.Y. : Medicom International, c1997-
References :
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239-1242.
Bozzani A, Arici V, Tavazzi G, et al. Acute arterial and deep venous thromboembolism in COVID-19 patients: risk factors and personalized therapy. Surgery. 2020;168:987-992.
Porfidia A, Pola R. Venous thromboembolism in COVID-19 patients. J Thromb Haemost. 2020;18:1516-1517.
Dobesh PP, Trujillo TC. Coagulopathy, venous thromboembolism, and anticoagulation in patients with COVID-19. Pharmacotherapy. 2020;40:1130-1151.
Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020;95:834-847.
Han H, Yang L, Liu R, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020;58:1116-1120.
Di Minno A, Ambrosino P, Calcaterra I, Di Minno MND. COVID-19 and venous thromboembolism: a meta-analysis of literature studies. Semin Thromb Hemost. 2020;46:763-771.
McBane II, Robert D, Torres Victor D, et al. Anticoagulation in COVID-19: a systematic review, meta-analysis and rapid guidance from the Mayo clinic. In: Mayo Clinic Proceedings. Elsevier, 2020;95:2467-2486. https://doi.org/10.1016/j.mayocp.2020.08.030.
Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18:1094-1099.
Du F, Jiang P, He S, Song D, Xu F. Antiplatelet therapy for critically ill patients: a pairwise and Bayesian network meta-analysis. Shock. 2018;49:616-624. https://doi.org/10.1097/SHK.0000000000001057.
Wang L, Li H, Gu X, Wang Z, Liu S, Chen L. Effect of antiplatelet therapy on acute respiratory distress syndrome and mortality in critically ill patients: a meta-analysis. PLoS One. 2016;11:e0154754. https://doi.org/10.1371/journal.pone.0154754.
Salah HM, Mehta JL. Meta-analysis of the effect of aspirin on mortality in COVID-19. Am J Cardiol. 2021;142:158-159. https://doi.org/10.1016/j.amjcard.2020.12.073.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71.
Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed May 2, 2021.
Chow JH, Khanna AK, Kethireddy S, et al. Aspirin use is associated with decreased mechanical ventilation, intensive care unit admission, and in-hospital mortality in hospitalized patients with coronavirus disease 2019. Anest Analg. 2021;132:930-941. https://doi.org/10.1213/ANE.0000000000005292.
Osborne TF, Veigulis ZP, Arreola DM, Mahajan SM, Röösli E, Curtin CM. Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration. PLoS One. 2021;16:e0246825. https://doi.org/10.1371/journal.pone.0246825.
Liu Q, Huang N, Li A, et al. Effect of low-dose aspirin on mortality and viral duration of the hospitalized adults with COVID-19. Medicine. 2021;100:e24544. https://doi.org/10.1097/MD.0000000000024544.
Viecca M, Radovanovic D, Forleo GB, Santus P. Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study. Pharmacol Res. 2020;158:104950. https://doi.org/10.1016/j.phrs.2020.104950.
Yuan S, Chen P, Li H, Chen C, Wang F, Wang DW. Mortality and pre-hospitalization use of low-dose aspirin in COVID-19 patients with coronary artery disease. J Cell Mol Med. 2021;25:1263-1273. https://doi.org/10.1111/jcmm.16198.
Kevorkian JP, Lopes A, Sène D, et al. Oral corticoid, aspirin, anticoagulant, colchicine, and furosemide to improve the outcome of hospitalized COVID-19 patients-the COCAA-COLA cohort study. J Infect. 2021;82:276-316. https://doi.org/10.1016/j.jinf.2021.02.008.
Merzon E, Green I, Vinker S, et al. The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID-19 infection. The FEBS Journal. 2021. https://doi.org/10.1111/febs.15784. Epub ahead of print.
Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9-14. https://doi.org/10.1016/j.thromres.2020.04.024.
Alamdari NM, Afaghi S, Rahimi FS, et al. Mortality risk factors among hospitalized COVID-19 patients in a major referral center in Iran. Tohoku J Exp Med. 2020;252:73-84. https://doi.org/10.1620/tjem.252.73.
Sahai A, Bhandari R, Koupenova M, et al. SARS-CoV-2 receptors are expressed on human platelets and the effect of aspirin on clinical outcomes in COVID-19 patients. Res Sq [Preprint]. 2020 Dec 23:rs.3.rs-119031. https://doi.org/10.21203/rs.3.rs-119031/v1.
Ornelas-Ricardo D, Jaloma-Cruz AR. Coronavirus disease 2019: hematological anomalies and antithrombotic therapy. Tohoku J Exp Med. 2020;251:327-336. https://doi.org/10.1620/tjem.251.327.
Mahajan P, Dass B, Radhakrishnan N, McCullough PA. COVID-19-associated systemic thromboembolism: a case report and review of the literature. Cardiorenal Med. 2020;10:462-469. https://doi.org/10.1159/000511800.
Indian Council of Medical Research (ICMR). Clinical Guidance for Management of COVID-19 Patients. https://www.icmr.gov.in/pdf/covid/techdoc/COVID19_Management_Algorithm_22042021_v1.pdf. Accessed April 19, 2021.
World Health Organization. WHO Recommends Follow-up Care, Low-Dose Anticoagulants for COVID-19 Patients. https://www.who.int/news-room/feature-stories/detail/who-recommends-follow-up-care-low-dose-anticoagulants-for-covid-19-patients. Accessed April 20, 2021.
National Institute of Health (NIH). COVID-19 Treatment Guidelines. Updated on February 11, 2021. https://www.covid19treatmentguidelines.nih.gov/antithrombotic-therapy/. Accessed April 20, 2021.
Entry Date(s) :
Date Created: 20210612 Latest Revision: 20210629
Update Code :
20210629
DOI :
10.1111/ijcp.14515
PMID :
34118111
Raport
COVID-19 infection, affecting every one of us from the last year. Emerging reports have indicated thromboembolism in serious cases of COVID-19. The aspirin is useful to reduce mortality of serious patients with acute respiratory distress syndrome without COVID-19. Thus, we have conducted a metanalysis to find out the role of aspirin in the mortality of COVID-19 patients using RevMan 5. A total of 10 studies containing 56 696 COVID-19 patients were found appropriate for quantitative analysis. The quality of articles was assessed using Newcastle-Ottawa scale. The fixed-effect model was used to calculate the odds ratio with 95% confidence interval (CI). The odd ratio was found to be 0.70 [0.63, 0.77] which indicates a lesser likelihood of having death in COVID-19 patients in aspirin group as compared with non-aspirin group. However, no effect 0.00 [-0.04, 0.04] was observed after the exclusion of outliers. Thus, further clinical evidence is required to make valid conclusion.
(© 2021 John Wiley & Sons Ltd.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies